Vera Therapeutics, Inc.
Company Stats
- Market Cap
- $2.3B
- as of Sep 30, 2026
- Enterprise Value
- $2.0B
- Shares Outstanding
- 72.1M
- Free Float
- 59.8%
Income Statement
- Operating Income
- -$315.5M
- Net Income
- -$299.6M
- EBITDA
- -$315.0M
Cash Flow
- Free Cash Flow
- -$241.7M
- FCF Yield
- -10.4%
- Owner FCF Yield
- -12.0%
Balance Sheet
- Cash & Equivalents
- $354.7M
- Total Debt
- $75.0M
- Net Cash
- $279.7M
Returns & Capital
- Buyback Yield, 3Y Avg
- 0.0%
- SBC, 3Y Avg
- $23.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$241.7M | — |
| FY2024 | — | -$135.7M | — |
| FY2023 | — | -$92.2M | — |
| FY2022 | — | -$67.7M | — |
| FY2021 | — | -$23.7M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
Stronger demand supports expansion as pricing diverges